Replies to post #81000 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

The company traded for $20 plus a share in its hey day on the Amex off the R&D related to this tech.....in 2004 Purdue came to discuss a potential partnership with this speck of a company......Elite will get sued by Purdue over Patent infringement rights.....and Elite will be allowed to market its products nonetheless......and Elite already owns 3 approved patents on its ADT tech....did Alpharma have their Intellectual Property Patents FDA approved prior to Embeda being marketed....BIG difference here...do some DD on that one....I could care less what the volume and PPS say right now.......hiring Nasrat who used to work at Alpharma that company used to own the IP rights to Embeda....they now belong to Pfizer....was a stroke of genius!........

Question: Was Alpharma worried that they may get forced legally to stop manufacturing and marketing Embeda back in 2008 given their patents had been approved yet?

The only way cnbc, bloomberg......and Pfizer already knows about us that is obvious.....begin to talk about Elite further.....is for the company to either partner with say Actavis or market their twice daily ADT opioid (with manufacturing help from Epic and marketing help from Actavis). Until one of those two things and likely both will happen......enjoy continuing to pick up the cheap seats below .115.

Hype ain't going to do it.....another Patent ain't going to do it.....but this next patent is a mother!!!!.......you still have to garner revenue before the PPS will move......plain and simple.....the only other way Partnership or getting bought out. Both are coming!!!

Further questions "snukoled"

[DR Ryan]

What does the share price have to do with our tech? I think by this point we should all know that on the OTC, the stock price and the company are completely separate. Once some actual study data starts rolling in, then the interest will spike. We are clearly in a quiet period now, and people know it. First study concludes on the 22nd, study data will be published probably mid January is my guess. Pivotal BE study on a 2nd product begins mid January. Next earnings mid February.

And big news wires really cover the same 5 stocks. Why? Because they know most sheep are in the same 5 stocks. Don't expect to see any stock that isn't AAPL, GOOG, LULU, etc. on CNBC anytime soon, much less a penny stock...unless its Fannie.